Better Therapy Brighter Outlook

About Lumosa

+
More LUMOSA
News Center

The US FDA has granted the Orphan Drug Status to Lumosa's LT2003, an anti-tumor targeting fusion protein, for the treatment of pancreatic cancer

Detail

Lumosa received LT5001 IND approval from TFDA for the treatment of uremic pruritus

Detail

Lumosa licensed LT1001 to Jemincare in China

Detail
+
More News
reSEARCH & DEVELOPMENT
Pipeline NameDisease Treatment
Compound SelectionPre-clinicalPhase 1Phase 2Phase 3NDALaunch
Pre-clinical
+
More Pipeline
+Close